XML 230 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1

Subsequent events (Details) - Subsequent Event - License and Collaboration Agreement - USD ($) $ in Billions		1 Months Ended
	Jan. 11, 2025	Jan. 31, 2025
Subsequent events
Percentage share of the income (loss) generated on U.S. sales		40.00%
Novartis
Subsequent events
Percentage share of the income (loss) generated on U.S. sales		60.00%
Novartis
Subsequent events
Cash proceeds from upfront payment on collaboration agreement	$ 1.0	$ 1.0
Novartis | Maximum
Subsequent events
Potential future proceeds contingent on achievement of developmental, regulatory and sales milestones and tiered royalties		$ 1.9

X

- Definition

The amount of cash inflow from collaborative agreement that was received as an upfront payment upon closing.

+ References

No definition available.

+ Details

Name:	ptct_CashProceedsCollaborativeAgreementUpfrontPayment
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of potential future proceeds which may be received contingent on achievement of specified developmental, regulatory and sales milestones and tiered royalties on ex-US sales.

+ References

No definition available.

+ Details

Name:	ptct_ContingentFutureProceedsBasedOnAchievementOfDevelopmentalRegulatoryAndSalesMilestonesAndTieredRoyalties
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The entity's share of the income (loss) generated on U.S. sales.

+ References

No definition available.

+ Details

Name:	ptct_IncomeLossOnU.s.DomesticSalesSharePercentage
Namespace Prefix:	ptct_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptct_LicenseAndCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=ptct_NovartisPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ptct_NovartisPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: